Objectives

After participating in this educational activity, attendees should be able to:
1.| Discuss the history of diabetic nephropathy progression over time.
2.| Discuss the ways to use new medications to slow nephropathy progression.
3.| Discuss how to avoid or manage the complications of novel agents approved for slowing nephropathy.

Faculty

Speaker Name
George Bakris, MD
The University of Chicago Medicine
Professor of Medicine
Section of Endocrinology, Diabetes & Metabolism
American Heart Association Comprehensive Hypertension Center

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

Dr. Bakris is a consultant for the following companies:  Merck, Bayer, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, HOrizon, Novo Nordisk DiaMedica Therapuetics, InRegen

None of the planners  for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.     

                                                        

Session date: 
Wednesday, November 17, 2021 - 8:00am to 9:00am
Location: 
Webinar Live
MA
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 BCIPE Instructional Hours

Please login or register to take this course.